Is the platelet function test effective in predicting blood loss in patients undergoing hepatic resection?

被引:0
|
作者
Gwon, Jun Gyo [1 ]
Ko, Sun-Young [2 ]
Kim, Hyokee [3 ]
机构
[1] Ulsan Univ, Coll Med, Asan Med Ctr, Div Vasc Surg,Dept Surg, Seoul, South Korea
[2] Korea Univ, Coll Med, Dept Lab Med, Seoul, South Korea
[3] Korea Univ, Coll Med, Dept Surg, Seoul, South Korea
关键词
Bleeding; Hepatectomy; Liver; Platelet function tests; CARDIAC-SURGERY; BLEEDING RISK; GUIDELINES; UTILITY;
D O I
10.4174/astr.2022.103.4.227
中图分类号
R61 [外科手术学];
学科分类号
摘要
Purpose: The platelet function analyzer (PFA)-100/200 is widely used to assess platelet function. However, its role in predicting the perioperative risk of bleeding in patients undergoing liver resection remains controversial. Therefore, we aimed to ascertain whether the platelet function test could be useful in predicting bleeding risk in patients undergoing hepatic surgery. Methods: The study participants were patients who underwent hepatectomy for hepatocellular carcinoma at our hospital over a period of 10 years from January 1, 2010 to May 31, 2020. PFA-200 values of these patients were divided into 2 groups; normal (n = 333) and prolonged (n = 39). Results: There were no significant differences regarding the volumes of calculated blood loss during surgery between the normal and prolonged PFA groups (879.55 +/- 1,046.50 mL vs. 819.74 +/- 912.64 mL, respectively; P = 0.733); intraoperative RBC transfusion (0.52 +/- 2.02 units vs. 0.26 +/- 1.02 units, P = 0.419) and postoperative RBC transfusion (0.24 +/- 1.17 units vs. 0.46 +/- 1.97 units, P = 0.306) were similar between the 2 groups, respectively. Multivariate analysis revealed no association between PFA closure time and calculated blood loss (hazard ratio, 1.06; P = 0.881). Moreover, there was no association between PFA closure time and preoperative laboratory results or assessment of tool-related liver function in multivariate analysis. Conclusion: There was no correlation between the amount of blood loss and platelet function in patients who underwent liver resection. In patients undergoing liver resection who are not managed on antiplatelet agents or do not have chronic kidney disease, the use of routine PFA is not recommended.
引用
收藏
页码:227 / 234
页数:8
相关论文
共 50 条
  • [41] Safety of an Enhanced Recovery Pathway for Patients Undergoing Open Hepatic Resection
    Clark, Clancy J.
    Ali, Shahzad M.
    Zaydfudim, Victor
    Jacob, Adam K.
    Nagorney, David M.
    PLOS ONE, 2016, 11 (03):
  • [42] The pharmacokinetics and safety of lidocaine in liver cancer patients undergoing hepatic resection
    He, Chaoqun
    Jin, Ying
    Zhang, Yang
    Zhang, Mengyu
    Di, Xiangjie
    Fu, Lisha
    Qi, Xiaohui
    Liu, Runhan
    Zheng, Li
    Wang, Zhenlei
    Li, Jingdong
    Tu, Faping
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 79 (06) : 829 - 839
  • [43] Incidence of benign pathology in patients undergoing hepatic resection for suspected malignancy
    Clayton, RAE
    Clarke, DL
    Currie, EJ
    Madhavan, KK
    Parks, RW
    Garden, OJ
    SURGEON JOURNAL OF THE ROYAL COLLEGES OF SURGEONS OF EDINBURGH AND IRELAND, 2003, 1 (01): : 32 - 38
  • [44] Anti-platelet therapy does not influence the outcome of patients undergoing hepatic resection for colorectal liver metastases, an observational study
    Boyd-Carson, H.
    Irving, G.
    Navarro, A. P.
    Cameron, I. C.
    Gomez, D. S.
    INTERNATIONAL JOURNAL OF SURGERY, 2018, 53 : 59 - 64
  • [45] Effects of splenectomy in patients with cirrhosis undergoing hepatic resection for hepatoceUular carcinoma
    Zhi-Xin Cao Xiao-Ping Chen Zai-De Wu
    World Journal of Gastroenterology, 2003, 9 (11) : 2460 - 2463
  • [46] Significance of zinc deficiency in patients with hepatocellular carcinoma undergoing hepatic resection
    Harimoto, Norifumi
    Araki, Kenichiro
    Muranushi, Ryo
    Hoshino, Kouki
    Yamanaka, Takahiro
    Hagiwara, Kei
    Ishii, Norihiro
    Tsukagoshi, Mariko
    Watanabe, Akira
    Shirabe, Ken
    HEPATOLOGY RESEARCH, 2022, 52 (02) : 210 - 220
  • [47] The pharmacokinetics and safety of lidocaine in liver cancer patients undergoing hepatic resection
    Chaoqun He
    Ying Jin
    Yang Zhang
    Mengyu Zhang
    Xiangjie Di
    Lisha Fu
    Xiaohui Qi
    Runhan Liu
    Li Zheng
    Zhenlei Wang
    Jingdong Li
    Faping Tu
    European Journal of Clinical Pharmacology, 2023, 79 : 829 - 839
  • [48] SIGNIFICANCE OF CLUSTERIN EXPRESSION IN PATIENTS WITH HEPATOCELLULAR CARCINOMA UNDERGOING HEPATIC RESECTION
    Chau, Gar-Yang
    Chi, Chin-Wen
    Kao, Hwa-Li
    ANNALS OF ONCOLOGY, 2011, 22 : v70 - v70
  • [49] PROGNOSTIC FACTORS OF HEPATOCELLULAR-CARCINOMA IN PATIENTS UNDERGOING HEPATIC RESECTION
    IZUMI, R
    SHIMIZU, K
    II, T
    YAGI, M
    MATSUI, O
    NONOMURA, A
    MIYAZAKI, I
    GASTROENTEROLOGY, 1994, 106 (03) : 720 - 727
  • [50] EFFECT OF TICLOPIDINE ON BLOOD-LOSS, PLATELET TURNOVER AND PLATELET DEPOSITION ON PROSTHETIC SURFACES IN PATIENTS UNDERGOING AORTOFEMORAL BYPASS-GRAFTING
    NEVELSTEEN, A
    MORTELMANS, L
    VANDECRUYS, A
    MERCKX, E
    VERHAEGHE, R
    THROMBOSIS RESEARCH, 1991, 64 (03) : 363 - 369